Cargando…

Coagulation Factor Xa (Recombinant), Inactivated-Zhzo (Andexanet Alfa) Hemostatic Outcomes and Thrombotic Event Incidence at an Academic Medical Center

Andexanet alfa is approved for the reversal of factor Xa inhibitors in patients with major bleeding events. We aimed to review the incidence of effective hemostasis with andexanet alfa in a real-world environment. This retrospective cohort included patients hospitalized for a major bleed that result...

Descripción completa

Detalles Bibliográficos
Autores principales:	Stevens, Victoria M., Trujillo, Toby, Mueller, Scott W., MacLaren, Robert, Reynolds, Paul M., Kiser, Tyree H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2019
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7019392/ https://www.ncbi.nlm.nih.gov/pubmed/31876159 http://dx.doi.org/10.1177/1076029619896619

Ejemplares similares

Retrospective Comparison of Andexanet Alfa and 4-Factor Prothrombin Complex for Reversal of Factor Xa-Inhibitor Related Bleeding
por: Stevens, Victoria M., et al.
Publicado: (2021)

Hemostatic Efficacy and Anti-FXa (Factor Xa) Reversal With Andexanet Alfa in Intracranial Hemorrhage: ANNEXA-4 Substudy
por: Demchuk, Andrew M., et al.
Publicado: (2021)

Reversing factor Xa inhibitors – clinical utility of andexanet alfa
por: Kaatz, Scott, et al.
Publicado: (2017)

Andexanet alfa for reversal of factor Xa inhibitor-associated anticoagulation
por: Carpenter, Elise, et al.
Publicado: (2019)

Measuring residual anti‐Xa activity of direct factor Xa inhibitors after reversal with andexanet alfa
por: Bourdin, Matthieu, et al.
Publicado: (2021)

Evaluation of oral factor Xa inhibitor‐associated extracranial bleeding reversal with andexanet alfa
por: Nederpelt, Charlie J., et al.
Publicado: (2020)

Andexanet Alfa for Reversal of Factor Xa Inhibitors in Intracranial Hemorrhage: Observational Cohort Study
por: Rauch, Sebastian, et al.
Publicado: (2022)

Reversal of Factor Xa Inhibitors by Andexanet Alfa May Increase Thrombogenesis Compared to Pretreatment Values
por: Siddiqui, Fakiha, et al.
Publicado: (2019)

Efficacy and Safety of Andexanet Alfa for Bleeding Caused by Factor Xa Inhibitors: A Systematic Review and Meta-Analysis
por: Shrestha, Dhan B, et al.
Publicado: (2021)

Andexanet Alfa: First Global Approval
por: Heo, Young-A
Publicado: (2018)

Institutional Experience of Using Andexanet Alfa
por: Khadka, Sushmita, et al.
Publicado: (2020)

A meta‐analysis of andexanet alfa and prothrombin complex concentrate in the treatment of factor Xa inhibitor–related major bleeding
por: Jaspers, Tessa, et al.
Publicado: (2021)

Correction to: Andexanet Alfa: First Global Approval
por: Heo, Young-A
Publicado: (2018)

In vitro reversal of direct factor Xa inhibitors: Direct comparison of andexanet alfa and prothrombin complex concentrates Cofact and Beriplex/Kcentra
por: Brinkman, Herm Jan M., et al.
Publicado: (2022)

Treatment of Factor-Xa Inhibitor-associated Bleeding with Andexanet Alfa or 4 Factor PCC: A Multicenter Feasibility Retrospective Study
por: Singer, Adam J., et al.
Publicado: (2023)

Difficult Intraoperative Heparinization Following Andexanet Alfa Administration
por: Watson, C. James, et al.
Publicado: (2019)

Differential Neutralization of Unfractionated Heparin and Enoxaparin by Andexanet Alfa
por: Lewis, Joseph, et al.
Publicado: (2022)

Successful use of an antithrombin for heparin resistance with andexanet alfa
por: Honda, Jun, et al.
Publicado: (2023)

Andexanet-Alfa-Associated Heparin Resistance in the Context of Hemorrhagic Stroke
por: Müther, Michael, et al.
Publicado: (2022)

Andexanet alfa — Recommendations for clinical use. Multidisciplinary experts’ standpoint
por: Kubica, Jacek, et al.
Publicado: (2023)

Reversal of apixaban and rivaroxaban with andexanet alfa prior to invasive or surgical procedures
por: Bradshaw, Paige Garber, et al.
Publicado: (2022)

Successful Nafamostat Mesilate Administration for Andexanet Alfa-Induced Heparin Resistance
por: Kitaura, Atsuhiro, et al.
Publicado: (2023)

How will UK hospitals use andexanet alfa? A review of local protocols
por: Glancy, Paula, et al.
Publicado: (2023)

Real-world clinical outcomes among US Veterans with oral factor xa inhibitor–related major bleeding treated with andexanet alfa or 4-factor prothrombin complex concentrate
por: Sutton, S. Scott, et al.
Publicado: (2023)

Lower mortality with andexanet alfa vs 4-factor prothrombin complex concentrate for factor Xa inhibitor-related major bleeding in a U.S. hospital-based observational study
por: Dobesh, Paul P., et al.
Publicado: (2023)

Coagulation Factor Xa
por: Brown, Mark A., et al.
Publicado: (2013)

Andexanet versus prothrombin complex concentrates: Differences in reversal of factor Xa inhibitors in in vitro thrombin generation
por: Lu, Genmin, et al.
Publicado: (2020)

Correction to: Real-world clinical outcomes among US Veterans with oral factor xa inhibitor-related major bleeding treated with andexanet alfa or 4-factor prothrombin complex concentrate
por: Sutton, S. Scott, et al.
Publicado: (2023)

Reversing anticoagulant effects of novel oral anticoagulants: role of ciraparantag, andexanet alfa, and idarucizumab
por: Hu, Tiffany Y, et al.
Publicado: (2016)

Assay-Based Differentiation in the Neutralization Profile of Unfractionated Heparin, Enoxaparin, and Fondaparinux by Andexanet Alfa
por: Siddiqui, Fakiha, et al.
Publicado: (2020)

Thrombin Generation Profile in Various Lymphoma Sub-Groups and Its Augmentation by Andexanet Alfa
por: Siddiqui, Fakiha, et al.
Publicado: (2020)

Andexanet Alfa for Specific Anticoagulation Reversal in Patients with Acute Bleeding during Treatment with Edoxaban
por: Benz, Alexander P., et al.
Publicado: (2022)

Rapid Detection of Apixaban by a ROTEM-Based Approach and Reversibility with Andexanet Alfa or DOAC-Stop
por: Taune, Viktor, et al.
Publicado: (2022)

Real-World Observational Review of Andexanet Alfa Prescribing and Utilization Outcomes at a Community Teaching Hospital
por: Sobolewski, Kristine A., et al.
Publicado: (2021)

Differential Neutralization of Apixaban, Betrixaban, Edoxaban, and Rivaroxaban by Andexanet Alfa as Measured by Whole Blood Thromboelastographic Analysis
por: Mehrotra, Siddharth, et al.
Publicado: (2022)

Therapeutic Hypothermia Following Cardiopulmonary Arrest: A Systematic Review and Meta-Analysis with Trial Sequential Analysis
por: Maclaren, Robert, et al.
Publicado: (2023)

Roles of factor Xa beyond coagulation
por: Ruf, Wolfram
Publicado: (2021)

Comparative evaluation of isavuconazonium sulfate, voriconazole, and posaconazole for the management of invasive fungal infections in an academic medical center
por: Van Matre, Edward T., et al.
Publicado: (2019)

Andexanet alfa effectively reverses edoxaban anticoagulation effects and associated bleeding in a rabbit acute hemorrhage model
por: Lu, Genmin, et al.
Publicado: (2018)

Andexanet alfa in the treatment of acute major bleeding related to apixaban and rivaroxaban: a profile of its use in the USA
por: Heo, Young-A
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_2s5brrfpv5livdi0ptn5eoo4ga